Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H29N3O5 |
| Molecular Weight | 367.44 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
InChI
InChIKey=ANZXOIAKUNOVQU-UHFFFAOYSA-N
InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3
Bambuterol is an active precursor of the selective beta2-adrenergic agonist terbutaline. Bambuterol is the bis-N,N-dimethyl-carbamate of terbutaline. Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
CNS Activity
Originator
PMID
| Title | Date | PMID |
|---|---|---|
| New lipophilic terbutaline ester prodrugs with long effect duration. | 1984 Jan |
|
| Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. | 1993 |
|
| Bambuterol and terbutaline in human cerebrospinal fluid and plasma. | 1993 |
|
| Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. | 1993 Nov |
|
| Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. | 1998 Jul |
|
| Can oral beta2 agonists cause heart failure? | 1998 Oct 3 |
|
| Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease. | 1999 Jan |
|
| Cholinesterases: new roles in brain function and in Alzheimer's disease. | 2003 Apr |
|
| Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase. | 2005 Jan |
|
| Stereoselective inhibition of human, mouse, and horse cholinesterases by bambuterol enantiomers. | 2008 Sep 25 |
|
| Influence of differential expression of acetylcholinesterase in brain and muscle on respiration. | 2009 Jan 1 |
Patent
Sample Use Guides
BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg. BAMBEC (Bambuterol hydrochloride) oral solution 1mg/ml. The recommended initial dose is 10mg (10ml). The dose may be increased to 20mg (20ml) after 1-2 weeks, depending on the clinical effect. In patients who previously have tolerated oral beta2-agonists well, the recommended initial dose is 20mg (20ml).
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QR03CC12
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
||
|
WHO-ATC |
R03CC12
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
81732-65-2
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
BAMBUTEROL
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
81732-65-2
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
54766
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
M2216
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | Merck Index | ||
|
CHEMBL521589
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
18751
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | RxNorm | ||
|
6601
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
SUB06095MIG
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
5304
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
C047766
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY | |||
|
C81692
Created by
admin on Tue Mar 06 11:52:14 UTC 2018 , Edited by admin on Tue Mar 06 11:52:14 UTC 2018
|
PRIMARY |
ACTIVE MOIETY
